CardioNova Of Russia Files For Clinical Trials Of Atherosclerosis Drug
This article was originally published in PharmAsia News
Executive Summary
Russia's CardioNova said pre-clinical trials of its AHRO-001 drug for treating dyslipidemia and preventing atherosclerosis produced excellent results leading to a filing for approval to begin human trials.